Purpose. Acinetobacter baumannii and Pseudomonas aeruginosa provoke serious infections, especially in intensive care unit (ICU) patients.
INTRODUCTION
Sepsis remains an important cause of morbidity and mortality in hospitalized patients worldwide, especially those treated in an intensive care unit (ICU) [1, 2] . Bloodstream infections (BSIs) comprise one of the commonest types of infections in critically ill patients, and they are often provoked by multidrug-resistant pathogens [2] . In Greek ICUs, Gram-negative bacteria cause the majority of such infections [3] . Among the most commonly isolated species are Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa [3] [4] [5] . Until recently, carbapenems were considered to be the most potent antibiotic class for the treatment of BSIs caused by the aforementioned pathogens, because of their high efficacy, even against extendedspectrum beta-lactamase (ESBL) producers [5] .
In the last decade, carbapenem-resistant clones (due to the acquisition of carbapenemase genes) of these pathogens have disseminated in Greek ICUs and permanently replaced the carbapenem-susceptible clones [3, 6, 7] . Thus, our armamentum is limited and includes colistin, aminoglycosides and tigecycline, to which P. aeruginosa is intrinsically resistant [3] . The fact that combination therapy is superior to monotherapy, while resistance against these antibiotics is rising, recently led to the use of variable drug combinations, such as colistin combined with either rifampicin or vancomycin, and fosfomycin, with controversial results [8] [9] [10] [11] .
The aim of the present study was to identify the risk factors for BSIs caused by P. aeruginosa or A. baumannii in ICU patients and determine factors that are associated with increased mortality.
METHODS Patients
This was an observational retrospective (case-control) study of patients hospitalized in the ICU of the University General Hospital of Patras (13 beds) during a 6-year period (January 2010-December 2015).
For P. aeruginosa, all of the BSI cases caused by carbapenemresistant P. aeruginosa (CR-Ps) were considered, and these were compared to all of the carbapenem-susceptible P. aeruginosa (CS-Ps) BSI cases. For A. baumannii, all of the carbapenem-resistant A. baumannii cases, and the control patients with no A. baumannii infection, were considered. Since only four patients were infected by carbapenemsusceptible A. baumannii, these cases were not included in the analysis. For each P. aeruginosa and carbapenem-resistant A. baumannii BSI case, four and two controls were included, respectively. The controls were ICU patients who had not been infected by the aforementioned pathogens, were hospitalized during the study period, and had been matched to cases according to their acute physiological and chronic health evaluation (APACHE) II score (±2 points), age (±2 years) and days at risk (±4 days; time from admission to BSI for cases and length of ICU stay for controls).
Epidemiological data
Epidemiological data were collected from the patients' chart reviews and the ICU computerized database (CriticusTM, University of Patras, Greece), and included demographic characteristics (age, sex and co-morbidities), severity scores for illness on admission and upon onset of infection, prior surgery (in the month before onset of infection), length of hospitalization, presence of invasive catheters, tracheotomy, prior BSI, antibiotic administration, corticosteroid administration and enteral or parenteral nutrition. Antibiotic administration during the ICU stay prior to the onset of infection was included.
Phenotypic identification and antibiotic susceptibility testing
If the patient developed fever (!38.0 C) or the clinical presentation was suggestive of BSI, two blood sets from peripheral sites and one blood set from the central venous line were obtained, as well as cultures from the suspected source (bronchial secretions, urine, pleural or peritoneal fluid, pus, catheter tip, etc.). P. aeruginosa and A. baumannii isolates were identified using the Vitek 2 Advanced Expert System (bioM erieux, Marcy l'Etoile, France). Antibiotic susceptibility was assessed using the agar disk diffusion method and the Etest (carbapenems, colistin and tigecycline) (bio-M erieux) according to EUCAST [12] . All imipenem-nonsusceptible P. aeruginosa isolates (MICs !1 mg l
À1
) were examined for metallo-beta-lactamase (MBL) production using the Etest MBL assay (bioM erieux).
Multilocus sequence typing (MLST) of Pseudomonas aeruginosa strains
Clones from the 24 available Pseudomonas aeruginosa strains (out of 29 cases), which were recovered from different patients during the outbreak of carbapenem-resistant BSIs in 2014, were defined by MLST according to the published protocols (https://pubmlst.org/paeruginosa/).
Definitions
A BSI was defined as at least one positive blood culture for either P. aeruginosa or A. baumannii with clinical presentation suggestive of infection, while its characterization as a primary or secondary BSI was determined according to the Centers for Disease Control and Prevention (CDC) definition [13] . Only the first episode of bacteraemia from each pathogen was included. The development of KPC-producing K. pneumoniae (KPC-Kp) BSIs was also included. Appropriate empirical antibiotic treatment was defined as treatment that included an antibacterial agent with in vitro activity against the infecting isolate, initiated within 72 h from the onset of infection, at an adequate dose.
Statistical analysis SPSS version 19.0 (SPSS, Chicago, IL, USA) software was used for all analyses. Categorical variables were compared using the Fisher exact test or 2 , as appropriate. Continuous variables were tested for normal distribution using the Shapiro-Wilk test. Normally distributed data were compared using the ANOVA test, while non-normally distributed data were compared with the Mann-Whitney U-test. Backward stepwise multiple logistic regression analysis used all those variables from the univariate analysis with a P<0.1. Odds ratios (ORs) and 95 % confidence intervals (CIs) were calculated to evaluate the strength of any association. Factors contributing to multicollinearity were excluded from the multivariate analysis. A survival curve was constructed using the Kaplan-Meier method in order to assess probability of survival for patients with an A. baumannii BSI with the administration of colistin with or without vancomycin. P<0.05 was considered to be statistically significant.
RESULTS
During 2010-15, 84 patients developed P. aeruginosa BSIs, corresponding to 4.0 episodes per 1000 ICU patient days (2.2 episodes of CR-Ps BSIs per 1000 ICU patient days). Most of these (46, 54.8 %) were caused by carbapenemresistant isolates (MBL-positive). Fig. 1 One hundred and twenty-nine patients developed BSIs due to CR-A. baumannii, corresponding to 6.1 episodes per 1000 ICU patient days (Fig. 1) . Table 2 shows the univariate analysis of risk factors for CR-A. baumannii BSIs. Multivariate analysis revealed that hospitalization during the summer months (P 0.032; OR 1.8; 95 % CI 1.1-3.1), prior KPCKp BSI (P 0.039; OR 1.9; 95 % CI 1.0-3.4), the number of antibiotics administered (P 0.029; OR 1.2; 95 % CI 1.0-1.3), and carbapenem (P 0.028; OR 2.7; 95 % CI 1.1-6.4) and cortisone administration (P 0.048; OR 1.6; 95 % CI 1.0-2.6) were independently associated with CR-A. baumannii BSIs.
The 30-day mortality rate for P. aeruginosa and A. baumannii BSI was 45.2 % (38 patients) and 39.5 % (51 patients), respectively. The results from the univariate analysis examining factors related to the mortality of these pathogens are shown in Tables 3 and 4 . The multivariate analysis revealed that SOFA score at the onset of infection (P 0.007; OR 1.4; 95 % CI 1.1-1.8), septic shock (P 0.013; OR 39.2; 95 % CI 2.2-712.6), age (P 0.032; OR 1.1; 95 % CI 1.0-1.1), prior KPC-Kp BSI (P 0.014; OR 7.9; 95 % CI 1.5-41.2) and BSI due to a carbapenem-resistant isolate (P 0.028; OR 5.3; 95 % CI 1.2-23.5) were significantly associated with P. aeruginosa BSI mortality, whereas empirical administration of at least one active antibiotic (P 0.023; OR 0.052; 95 % CI 0.004-0.673) was identified as a predictor of a good prognosis. Septic shock (P<0.001; OR 16.4; 95 % CI 4.2-64.1) and SAPS II at the onset of infection (P 0.005; OR 1.1; 95 % CI 1.0-1.2) were independently associated with CR-A. baumannii BSI mortality, whereas empirical administration of at least one active antibiotic (P 0.034; OR 0.159; 95 % CI 0.029-0.872) and colistin-vancomycin co-administration (P 0.041; OR 0.328; 95 % CI 0.112-0.958) were identified as predictors of a good prognosis. Fig. 2 depicts the Kaplan-Meier curve for survival probability with reference to the administration of colistin with or without vancomycin.
DISCUSSION
We attempted to identify risk factors for P. aeruginosa or A. baumannii BSIs among critically ill patients, and also determine what factors influence the outcomes for patients with such infections. In total, 213 BSI episodes involving either pathogen were observed, with a mortality rate that surpassed 40 %.
The most important finding is that KPC-Kp BSIs led to bacteraemia by either A. baumannii or P. aeruginosa. This may be explained by the fact that all carbapenem-resistant Gram-negative pathogens share the same risk factors, such as antibiotic exposure, invasive procedures, co-morbidities and cross-transmission via healthcare personnel [3, 14] . It has been proven that episodes of severe sepsis and the administration of corticosteroids take a significant toll on the already impaired immunity system of critically ill patients [15] . It has also been shown that patients who are taking corticosteroids have a propensity to develop P. aeruginosa infection, while this association has not previously been detected for A. baumannii infections [16] . The development of a P. aeruginosa BSI after a KPC-Kp BSI was associated with a higher mortality compared to that for patients without a prior KPC-Kp episode. The finding that the majority of A. baumannii BSIs and KPC-Kp BSIs are without primary foci (lung, urine, central catheter) suggests that these bacteria translocate from the gastrointestinal tract to extraintestinal sites, such as the bloodstream, which underlines the importance of this phenomenon in critically ill patients [17, 18] . In previous reports [19, 20] , KPC-Kp BSIs predisposed patients to candidaemia infection, probably because of intestinal translocation of Candida spp. in critically ill patients with multiple risk factors.
Carbapenem administration was reported to be commonly associated with carbapenem-resistant bacteria [21, 22] . Even though carbapenem administration was an important risk factor for the development of CR-A. baumannii, it was not associated with the development of BSIs by CR-Ps. This later finding was probably due to the fact that 54.3 % of the cases were reported in 2014 during an outbreak that was controlled the year after by the reinforcement of infection control measures (Fig. 1) . The number of antibiotics administered was also previously found to be significantly associated with CR-A. baumannii BSIs [23] .
Seasonality is an important issue for healthcare-associated infections [24] . As previously shown, the incidence of both P. aeruginosa and A. baumannii BSI is higher during the summer months [25] . Infection incidence for the aforementioned pathogens in the ICU correlates with environmental humidity and temperature [26] . Moreover, the outbreak of carbapenem-resistant P. aeruginosa during the second semester of 2014 was associated with the emergence of the ST227 clone, which belongs to the international clonal complex CC235, which is known for its worldwide dissemination and carriage of carbapenemase genes (mainly bla VIM or bla IMP ) [27] . Another interesting feature is that even though different clones were identified during the present study as compared to a previous one performed during 2006-7 among patients hospitalized in the same ICU (ST235, ST111, ST253, ST309, ST639), the predominant clones of both studies (ST227 and ST235) belonged to the same clonal complex (CC235) [6] . Our results reinforce the need for continuous surveillance of the changing epidemiology. An important finding of the present study is the role of tigecycline administration in the induction of P. aeruginosa BSIs. Thirty out of 61 (49.2 %) patients who received tigecycline developed P. aeruginosa infection. Even though clinical trials did not show higher superinfection rates than for comparators in patients with tigecycline treatment [28, 29] , other studies reported such a superinfection [30, 31] . This may be explained by the fact that tigecycline Data are number (%) of patients or mean ± standard deviation.
CR, carbapenem-resistant; KPC-Kp, KPC-producing K. pneumoniae; APACHE II, acute physiology and chronic health evaluation II; SAPS II, simplified acute physiology score II; SOFA, sequential organ failure assessment. *After ICU admission, all patients were intubated, mechanically ventilated and continuously monitored with a central venous catheter, an arterial catheter and a urinary catheter. The number of catheters does not include the aforementioned catheters.
treatment disrupts the intestinal flora by affecting most anaerobic Gram-positive and Gram-negative microorganisms, leading to multiplication and the establishment of tigecycline-resistant bacteria, such as P. aeruginosa. This finding may have serious implications in the future due to the widespread use of tigecycline, especially for the treatment of carbapenem-resistant A. baumannii and K. pneumoniae [3] .
Mortality for both pathogens was significantly influenced by the development of septic shock. Sepsis is still one of the most important causes of morbidity and mortality in critically ill patients globally [1, 23] . In the present study 79 (67.5 %) out of 117 patients with septic shock died, regardless of appropriate antibiotic administration. The severity of disease upon the onset of BSI as depicted by SOFA or SAPS II scores has been shown to be significantly associated with higher mortality [32] [33] [34] . Mortality for both pathogens is high (45.2 % for P. aeruginosa and 39.5 % for A. baumannii) and comparable to that for KPCKp BSIs (43.4 %) [3] . Even though P. aeruginosa isolates were susceptible to more antibiotics than those for
A. baumannii and KPC-Kp, the BSI mortality rate was the same, suggesting that P. aeruginosa is more virulent, and that the increased mortality for A. baumannii and KPCKp BSI is due to the limited armamentum against these bacteria [3, 5, 7] . Appropriate treatment with at least one active antibiotic was found to be associated with better survival for patients suffering from P. aeruginosa or A. baumannii [35, 36] . In contrast to K. pneumoniae BSIs, which need to be treated by a combination of active antibiotics, monotherapy showed better results than combination therapy for BSIs caused by P. aeruginosa and A. baumannii [3] . Carbapenem resistance among P. aeruginosa BSIs reduces the available treatment options and, as shown in a meta-analysis, carbapenem resistance among P. aeruginosa BSIs had a deleterious impact on survival [37] .
The combination of colistin with vancomycin, an antibiotic that should ordinarily have no effect on Gram-negative bacteria, improved the survival of patients with A. baumannii BSIs (Fig. 1) , reinforcing the results from previous reports that included in vitro experiments using time-kill assays and/or in vivo studies [8, 11] . This could be significant for the treatment of carbapenem-resistant A. baumannii infections, since our therapeutic options are limited [8] .
This study has some limitations, since it is a case-control study. Moreover, PCR was not performed to identify the carbapenemase genes in the phenotypically detected carbapenem-resistant isolates.
To conclude, KPC-Kp infection predisposes ICU patients to A. baumannii and P. aeruginosa BSIs. The outbreak of carbapenem-resistant P. aeruginosa during 2014 was mainly due to the dissemination of the ST227 clone, which belongs to the highly successful CC235 clonal complex. Tigecycline administration is independently associated with the development of P. aeruginosa bacteraemia. Septic shock is associated with higher mortality, while the administration of at 
